IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) Stock Price, Forecast & Analysis
Europe • Euronext Milan • BIT:1IOVA • US4622601007
1IOVA.MI Key Statistics, Chart & Performance
The current stock price of 1IOVA.MI is 2.323 EUR.
1IOVA.MI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to 1IOVA.MI.
1IOVA.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to 1IOVA.MI. 1IOVA.MI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
1IOVA.MI Financial Highlights
Over the last trailing twelve months 1IOVA.MI reported a non-GAAP Earnings per Share(EPS) of -1.02. The EPS increased by 20.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.94% | ||
| ROE | -56.62% | ||
| Debt/Equity | 0 |
1IOVA.MI Forecast & Estimates
18 analysts have analysed 1IOVA.MI and the average price target is 7.3 EUR. This implies a price increase of 214.45% is expected in the next year compared to the current price of 2.323.
For the next year, analysts expect an EPS growth of 17% and a revenue growth 58.86% for 1IOVA.MI
1IOVA.MI Ownership
1IOVA.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 27.4 | 43.108B | ||
| ARGX | ARGENX SE | 27.14 | 43.046B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.737B | ||
| 2X1 | ABIVAX SA | N/A | 7.625B | ||
| ABVX | ABIVAX SA | N/A | 7.601B | ||
| GLPG | GALAPAGOS NV | N/A | 1.857B | ||
| GXE | GALAPAGOS NV | N/A | 1.853B | ||
| 6IV | INVENTIVA SA | N/A | 978.821M | ||
| IVA | INVENTIVA SA | N/A | 963.467M | ||
| NANO | NANOBIOTIX | N/A | 868.079M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1IOVA.MI
Company Profile
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 838 full-time employees. The company went IPO on 2008-06-20. The company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The company is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. The company also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.
Company Info
IOVANCE BIOTHERAPEUTICS INC
825 Industrial Road, 4th Floor
San Carlos CALIFORNIA US
Employees: 838
Phone: 16502607120
IOVANCE BIOTHERAPEUTICS INC / 1IOVA.MI FAQ
Can you describe the business of IOVANCE BIOTHERAPEUTICS INC?
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 838 full-time employees. The company went IPO on 2008-06-20. The company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The company is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. The company also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.
What is the stock price of IOVANCE BIOTHERAPEUTICS INC today?
The current stock price of 1IOVA.MI is 2.323 EUR. The price increased by 1% in the last trading session.
What is the dividend status of IOVANCE BIOTHERAPEUTICS INC?
1IOVA.MI does not pay a dividend.
What is the ChartMill rating of IOVANCE BIOTHERAPEUTICS INC stock?
1IOVA.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) stock?
18 analysts have analysed 1IOVA.MI and the average price target is 7.3 EUR. This implies a price increase of 214.45% is expected in the next year compared to the current price of 2.323.
What sector and industry does IOVANCE BIOTHERAPEUTICS INC belong to?
IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) operates in the Health Care sector and the Biotechnology industry.
What is IOVANCE BIOTHERAPEUTICS INC worth?
IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) has a market capitalization of 922.16M EUR. This makes 1IOVA.MI a Small Cap stock.